- Investing.com
तुलना करने के लिए मीट्रिक्स | NUVB | क्षेत्र सेक्टर - संबंधित क्षेत्र की कंपनियों के व्यापक समूह से मेट्रिक्स का औसत हेल्थकेयर | संबंध संबंधNUVBपीअर्सक्षेत्र | |
|---|---|---|---|---|
पी/ई अनुपात | −15.5x | −1.8x | −0.4x | |
PEG अनुपात | −0.52 | −0.15 | 0.00 | |
क़ीमत/बुक | 9.1x | 1.6x | 2.6x | |
क़ीमत / एलटीएम बिक्री | 13.6x | 2.4x | 3.1x | |
अपसाइड (विश्लेषक लक्ष्य) | 76.3% | 60.5% | 48.2% | |
उचित मूल्य अपसाइड | अनलॉक करें | 13.5% | 5.8% | अनलॉक करें |
Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on developing product candidates for cancer treatment. The company’s lead product candidate is IBTROZI (taletrectinib), a ROS1 inhibitor for the treatment of patients with ROS1+ non-small cell lung cancer. It is also developing Safusidenib, an inhibitor of mutant isocitrate dehydrogenase 1 in phase 3 clinical trials for the maintenance treatment of high-risk or high-grade IDH1-mutant astrocytoma with safusidenib against placebo. The company was founded in 2018 and is headquartered in New York, New York.